UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to_________ Commission File Number: 001-39949 _________________ Hyperfine, Inc. (Exact name of registrant a ...

财务数据和关键指标变化 - 第二季度收入为3.4亿美元,同比增长近一倍 [11][12] - 毛利润为1.4亿美元,毛利率为43%,较上年同期由负转正 [33] - 研发费用为5.3亿美元,销售及管理费用为7.8亿美元,净亏损为10.6亿美元 [33][34] - 公司现金和现金等价物为93.9亿美元,第二季度现金消耗为10.1亿美元 [34] 各条业务线数据和关键指标变化 - 公司在第二季度实现了14台Swoop系统的商业销售 [12] - 国际市场和与King's College London的合作是销售的主要驱动因素 [12][13] 各个市场数据和关键指标变化 - 国际市场销售占据了第二季度的主要部分,公司已完成了对King's College London的全部交付 [58][59] - 第三季度及以后,公司将更多关注美国市场,正在与多家美国医院系统建立合作关系 [29][59] 公司战略和发展方向及行业竞争 - 公司围绕三大支柱(创新、临床证据和商业拓展)持续推进 [14][18][25] - 在创新方面,公司持续投资硬件和AI软件以提升超低场MRI的图像质量和临床价值 [14][15][16][17] - 在临床证据方面,公司正在开展多项临床研究,包括急性卒中、儿科脑积水和ECMO患者成像等 [18][19][20][21][23] - 在商业拓展方面,公司正在美国市场建立销售、实施和使用支持团队,并获得新的3年3百万美元的研究资助 [25][26][27][29] - 公司看好超低场MRI在阿尔茨海默病新药监测等新兴应用的潜力 [24] 管理层对经营环境和未来前景的评论 - 公司保持谨慎的指引,预计2023年全年收入为10-14亿美元,毛利率40%-50%,现金消耗40-45亿美元 [35][36] - 公司对未来发展持乐观态度,将继续投资创新、临床证据和商业拓展,同时保持良好的成本管控 [31][37] - 公司任命首席运营官,加强产品开发、临床科学和运营等关键领域的领导力 [39][40] 问答环节重要的提问和回答 问题1 **Neil Chatterji 提问** 询问第二季度订单的构成情况,以及对下半年销售预期的假设 [56][57] **Maria Sainz 回答** 公司不会披露具体的地理分布,第二季度主要是国际市场订单,下半年将更多关注美国市场,预计定价将继续改善,但也存在一些季节性因素 [58][59] 问题2 **Neil Chatterji 提问** 询问公司在软件升级方面的进展,以及2024年的潜在驱动因素 [62][63] **Maria Sainz 回答** 公司在提升图像质量和性能方面持续投入,未来将推出新的软件版本,并开展一些新的临床应用可行性研究,为2024年的发展奠定基础 [63][64][65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________to_________ Commission File Number: 001-39949 _________________ Hyperfine, Inc. (Exact name of registrant as spe ...

Hyperfine, Inc. (NASDAQ:HYPR) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Maria Sainz - President, Chief Executive Officer Brett Hale - Chief Administrative Officer, Incoming Chief Financial Officer Marissa Bych - Investor Relations, The Gilmartin Group Conference Call Participants Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Neil Chatterji - B. Riley Operator At this time all participants are in listen-only mode. After the speakers presentation there will be a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-Q _________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 _________________ Hyperfine, Inc. (Exact name of registrant as specified in its chart ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39949 Hyperfine, Inc. (Exact name of registrant as specified in its charter) Delaware 98-1569027 (State or other jurisdiction of (I. ...

Hyperfine, Inc. (NASDAQ:HYPR) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Maria Sainz - President, Chief Executive Officer Brett Hale - Chief Administrative Officer, Incoming Chief Financial Officer Marissa Bych - Investor Relations, The Gilmartin Group Conference Call Participants Larry Biegelsen - Wells Fargo Kevin Joaquin - Evercore ISI Neil Chatterji - B. Riley Operator Thank you for standing by and welcome to Hyperfine’s Fourth Quarter and Full Year 2022 Conference C ...

Hyperfine, Inc. (NASDAQ:HYPR) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Marissa Bych – Investor Relations Maria Sainz – President and Chief Executive Officer Alok Gupta – Chief Financial Officer Scott Huennekens – Executive Chairman Conference Call Participants Larry Biegelsen – Wells Fargo Neil Chatterji – B. Riley Larry Biegelsen – Wells Fargo Operator Good afternoon, and welcome to HyperfineÂ's Third Quarter 2022 Earnings Conference Call. At this time, all partici ...

HYPERFINE Defining the Future of Diagnostics at the Point of Care Corporate Presentation | November 2022 © 2022 Hyperfine, Inc. Forward Looking Statements This presentation includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-lookin ...

Hyperfine, Inc. (NASDAQ:HYPR) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group LLC Scott Huennekens - Interim President and Chief Executive Officer Alok Gupta - Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Operator Ladies and gentlemen, thank you for standing by and welcome to the Hyperfine Q2 2022 Earnings Conference Call. At this time all participants are in a listen-only mode ...